Zynerba Pharmaceuticals Receivables

Zynerba Pharmaceuticals (ZYNE) currently reports a receivables of $1.3M as of June 2023. That compares with $1.5M in the prior-year period — down 11.2% year over year. Use the charts on this page to explore Zynerba Pharmaceuticals's receivables history and peer comparisons.

Zynerba Pharmaceuticals's receivables decreased from $1.5M to $1.3M — a 11.2% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zynerba Pharmaceuticals reported $1.3M in receivables as of June 2023. That compares with $1.5M in the prior-year period — down 11.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zynerba Pharmaceuticals, and consider following ZYNE for alerts when major investors trade the stock.

Zynerba Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $1.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZYNE with unrelated industries.